Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 2/2015

01-04-2015 | ORIGINAL ARTICLE

Central and Peripheral Irisin Differentially Regulate Blood Pressure

Authors: Weizhen Zhang, Lin Chang, Chao Zhang, Ruthann Zhang, Ziru Li, Biaoxin Chai, Jiyao Li, Eugene Chen, Michael Mulholland

Published in: Cardiovascular Drugs and Therapy | Issue 2/2015

Login to get access

Abstract

Introduction

Irisin is a newly identified 112 amino acid hormone, derived as a product of fibronectin type III domain containing 5 (FNDC5), which is highly related to metabolic activity in skeletal muscle and brown fat. The effects of irisin on cardiovascular functions are unknown.

Purpose

To explore the effects of central and peripheral irisin on cardiovascular functions.

Methods

Irisin was either administrated into 3rd ventricle of rats or intravenously, and its effects on blood pressure and cardiac contractibility measured.

Results

Administration of recombinant human irisin into the 3rd brain ventricle of rats activated neurons in the paraventricular nuclei of the hypothalamus. Central administration of irisin increased blood pressure and cardiac contractibility. Exogenous irisin reversed atenolol-induced inhibition of cardiac contractibility. In contrast, peripheral administration of irisin reduced blood pressure in both control and spontaneously hypertensive rats. Irisin dilated mesenteric artery rings through ATP-sensitive potassium channels.

Conclusion

Our studies indicate that central and peripheral irisin may differentially regulate cardiovascular activities.
Appendix
Available only for authorised users
Literature
1.
Bostrom P, Wu J, Jedrychowski MP, et al. A pgc1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463–8.CrossRefPubMedCentralPubMed
2.
Brenmoehl J, Albrecht E, Komolka K, et al. Irisin is elevated in skeletal muscle and serum of mice immediately after acute exercise. Int J Biol Sci. 2014;10:338–49.CrossRefPubMedCentralPubMed
3.
Norheim F, Langleite TM, Hjorth M, et al. The effects of acute and chronic exercise on pgc-1alpha, irisin and browning of subcutaneous adipose tissue in humans. FEBS J. 2014;281:739–49.CrossRefPubMed
4.
Hecksteden A, Wegmann M, Steffen A, et al. Irisin and exercise training in humans - results from a randomized controlled training trial. BMC Med. 2013;11:235.CrossRefPubMedCentralPubMed
5.
Kraemer RR, Shockett P, Webb ND, Shah U, Castracane VD. A transient elevated irisin blood concentration in response to prolonged, moderate aerobic exercise in young men and women. Horm Metab Res. 2014;46:150–4.PubMed
6.
Lee P, Linderman JD, Smith S, et al. Irisin and fgf21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab. 2014;19:302–9.CrossRefPubMed
7.
Zhang Y, Li R, Meng Y, et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 map kinase and erk map kinase signaling. Diabetes. 2014;63:514–25.CrossRefPubMed
8.
Lopez-Legarrea P, de la Iglesia R, Crujeiras AB, et al. Higher baseline irisin concentrations are associated with greater reductions in glycemia and insulinemia after weight loss in obese subjects. Nutr Diabetes. 2014;4:e110.CrossRefPubMedCentralPubMed
9.
Sesti G, Andreozzi F, Fiorentino TV, et al. High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol. 2014. doi:10.​1007/​s00592-014-0576-0.PubMedCentral
10.
Teufel A, Malik N, Mukhopadhyay M, Westphal H. Frcp1 and frcp2, two novel fibronectin type iii repeat containing genes. Gene. 2002;297:79–83.CrossRefPubMed
11.
Ferrer-Martinez A, Ruiz-Lozano P, Chien KR. Mouse pep: a novel peroxisomal protein linked to myoblast differentiation and development. Dev Dyn. 2002;224:154–67.CrossRefPubMed
12.
Dun SL, Lyu RM, Chen YH, Chang JK, Luo JJ, Dun NJ. Irisin-immunoreactivity in neural and non-neural cells of the rodent. Neuroscience. 2013;240:155–62.CrossRefPubMedCentralPubMed
13.
Aydin S, Kuloglu T, Aydin S, et al. A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues. Peptides. 2014;61C:130–6.CrossRef
14.
Hashemi MS, Ghaedi K, Salamian A, et al. Fndc5 knockdown significantly decreased neural differentiation rate of mouse embryonic stem cells. Neuroscience. 2013;231:296–304.CrossRefPubMed
15.
Moon HS, Dincer F, Mantzoros CS. Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse h19-7 hippocampal cell lines. Metabolism. 2013;62:1131–6.CrossRefPubMedCentralPubMed
16.
Piya MK, Harte AL, Sivakumar K, et al. The identification of irisin in human cerebrospinal fluid: Influence of adiposity, metabolic markers, and gestational diabetes. Am J Physiol Endocrinol Metab. 2014;306:E512–8.CrossRefPubMed
17.
Walls EK, Wishart TB. Reliable method for cannulation of the third ventricle of the rat. Physiol Behav. 1977;19:171–3.CrossRefPubMed
18.
Li JY, Chai BX, Zhang W, Wang H, Mulholland MW. Expression of ankyrin repeat and suppressor of cytokine signaling box protein 4 (asb-4) in proopiomelanocortin neurons of the arcuate nucleus of mice produces a hyperphagic, lean phenotype. Endocrinology. 2010;151:134–42.CrossRefPubMedCentralPubMed
19.
20.
Chang L, Villacorta L, Li R, et al. Loss of perivascular adipose tissue on peroxisome proliferator-activated receptor-gamma deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis. Circulation. 2012;126:1067–78.CrossRefPubMedCentralPubMed
21.
Rahmouni K, Morgan DA. Hypothalamic arcuate nucleus mediates the sympathetic and arterial pressure responses to leptin. Hypertension. 2007;49:647–52.CrossRefPubMed
22.
Mark AL, Rahmouni K, Correia M, Haynes WG. A leptin-sympathetic-leptin feedback loop: potential implications for regulation of arterial pressure and body fat. Acta Physiol Scand. 2003;177:345–9.CrossRefPubMed
23.
Correia ML, Morgan DA, Mitchell JL, Sivitz WI, Mark AL, Haynes WG. Role of corticotrophin-releasing factor in effects of leptin on sympathetic nerve activity and arterial pressure. Hypertension. 2001;38:384–8.CrossRefPubMed
24.
Pardridge WM. Recent developments in peptide drug delivery to the brain. Pharmacol Toxicol. 1992;71:3–10.25.CrossRefPubMed
25.
Timmons JA, Baar K, Davidsen PK, Atherton PJ. Is irisin a human exercise gene? Nature. 2012;488:E9–10. discussion E10-11.CrossRefPubMed
26.
Kurdiova T, Balaz M, Vician M, et al. Effects of obesity, diabetes and exercise on fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol. 2014;592:1091–107.CrossRefPubMedCentralPubMed
27.
Erickson HP. Irisin and fndc5 in retrospect: an exercise hormone or a transmembrane receptor? Adipocyte. 2012;2:289–93.CrossRef
Metadata
Title
Central and Peripheral Irisin Differentially Regulate Blood Pressure
Authors
Weizhen Zhang
Lin Chang
Chao Zhang
Ruthann Zhang
Ziru Li
Biaoxin Chai
Jiyao Li
Eugene Chen
Michael Mulholland
Publication date
01-04-2015
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 2/2015
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-015-6580-y

Other articles of this Issue 2/2015

Cardiovascular Drugs and Therapy 2/2015 Go to the issue

ORIGINAL ARTICLE

Effect of High Dose Statin Pretreatment on Endothelial Progenitor Cells After Percutaneous Coronary Intervention (HIPOCRATES Study)

EDITORIAL

Endothelial Progenitor Cells and Percutaneous Coronary Artery Intervention

REVIEW ARTICLE

Update of Clinical Trials of Anti-PCSK9 Antibodies

Erratum

Erratum to: K+ Channels Expression in Hypertension After Arterial Injury, and Effect of Selective Kv1.3 Blockade with PAP-1 on Intimal Hyperplasia Formation

REVIEW ARTICLE

Pharmacotherapy and Other Therapeutic Modalities for Managing Arrhythmogenic Right Ventricular Cardiomyopathy

REVIEW ARTICLE

Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management